High risk human papillomavirus genotyping in clinical samples: Evaluation of different commercial tests

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 127-138

  Paolini, F ^a   Rollo, F ^a,c   Brandi, R ^a   Benevolo, M ^a   Marianp, L ^b   Cercato, M C ^a   Vocaturo, A ^a   Venuti, Aldo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Department of Gynaecologic Oncology ^*  (Italy)

^c EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Commercial tests; Diagnosis; Genotyping; HPV; Vaccine monitoring

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; BIOASSAY; DIAGNOSTIC TEST; FEMALE; GENOTYPE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS CAPSID; VIRUS DETECTION; WART VIRUS; COHORT ANALYSIS; CYTODIAGNOSIS; HISTOLOGY; HUMAN PAPILLOMAVIRUS DNA TEST; MIXED INFECTION; MOLECULAR HYBRIDIZATION; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; VIRUS TYPING; ANALYTICAL EQUIPMENT; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PROSPECTIVE STUDY; RISK; UTERINE CERVIX TUMOR;

VIRUS DNA;

ADULT; AGED; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 79957839900     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400115     Document Type: Article

References (32)

1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50. (Pubitemid 37328947)
2. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27. (Pubitemid 38737395)
3. Munoz N, Bosch FX., De Sanjose S, Horrero R, Castellague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J 2003; 348:518-27. (Pubitemid 36159887)
4. The Atypical Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomised trial. J Natl Cancer Inst 2000; 92:397-02.
5. Rozendaal L, Walboomers JM, Van der Linden JC, Voorhorst FJ, Kenemans, Heimerhorst TJ, van Ballegooijen M, Meijer CJ. PCR based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996; 68:766-9. (Pubitemid 27062038)
6. Rozendaal L, Westerga J, Van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000; 53:606-11. (Pubitemid 30640172)
7. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, De Schipper FA, Meijer CJ. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001; 195:300-06.
8. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337:1754.
9. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127:959-68. (Pubitemid 36994855)
10. Sedati A, Mariani L, Giovinazzi R, Badaracco G, Venuti A, Atlante G. Prognostic value of infection from human papillomavirus 16 and 18 in the follow-up of patients submitted to conization for cervical intraepithelial neoplasia grade III. Cervix Low Female Genital Tract 1991; 9:25-9.
11. Nobbenhuis M, Meijer C, Van den Brule A, Rozendaal L, Voorhorst F, Risse EK, Verheijen RH, Heimerhorst TJ. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84:796-801. (Pubitemid 32275653)
12. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, Pahisa J, Ordi J. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006; 103:631-6. (Pubitemid 44602179)
13. Badaracco G, Venuti A, Sedati A, Marcante ML. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002; 67:574-82. (Pubitemid 34747680)
14. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9. (Pubitemid 41417924)
15. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989; 7:209-14.
16. De Roda Husman AM, Snijders PJ, Stel HV, Van den Brule AJ, Meijer CJ, Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995; 72:412-7.
17. Jacobs MV, Snijders PJ, Van den Brule AJ, Heimerhorst TJ, Meijer CLJM, Walboomers JMM. A general primer GP5(+)/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 highrisk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35:791-5. (Pubitemid 27083888)
18. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239:487-91. (Pubitemid 18084310)
19. Fleiss JL. Statistical methods for rates and proportion. 2nd ed. New York: John Wiley & Sons Inc. 1981.
20. Poljak M, Fujs K, Seme K, Kocjan BJ, Vrtacnik-Bokal E. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatovenerol Alp Panonica Adriat 2005; 14:147-52. (Pubitemid 43028734)
21. Carozzi F, Bisanzi S, Sani C, Zappa M, Cecchini S, Ciatto S, Confortini M. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007; 45:364-9.
22. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007; 45:2130-7. (Pubitemid 47203782)
23. Tropé A, Sjøborg K, Eskild A, et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol 2009; 47:2458-64.
24. Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HCII assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin Microbiol 2006; 44:2141-6. (Pubitemid 43902166)
25. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9. (Pubitemid 41417924)
26. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97:1066-71. (Pubitemid 41417923)
27. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-15. (Pubitemid 38584984)
28. Klug SJ, Molijn A, Schopp B, et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008; 80:1264-74. (Pubitemid 351706007)
29. Shin HR, Franceschi S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004; 190:468-76. (Pubitemid 38982082)
30. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, Changchien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006; 101:40-5.
31. Miyashita M, Agdamag DM, Sasagawa T, et al. High-risk HPV types in lesions of the uterine cervix of female 12 commercial sex workers in the Philippines. J Med Virol 2009; 81:545-51.
32. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus J Virol Methods 2009; 156:77-83.